Ignite Creation Date:
2024-05-06 @ 7:22 AM
Last Modification Date:
2024-10-26 @ 11:47 AM
Study NCT ID:
NCT02521051
Status:
UNKNOWN
Last Update Posted:
2019-11-26
First Post:
2015-07-20
Brief Title:
Phase III Trial of Alectinib and Bevacizumab in Patients With Advanced Anaplastic Lymphoma Kinase ALK-Positive Non-Small Cell Lung Cancer
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10
Start Date Type:
None
Primary Completion Date:
2020-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-06
Completion Date Type:
ESTIMATED
First Submit Date:
2015-07-20
First Submit QC Date:
August 7 2015
Study First Post Date:
2015-08-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-11-25
Last Update Post Date:
2019-11-26
Last Update Post Date Type:
ACTUAL